Literature DB >> 23712183

Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?

Paolo Michieli1, Federica Di Nicolantonio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23712183     DOI： 10.1038/nrclinonc.2013.86

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Authors:  Anand G Patel; Silvana B De Lorenzo; Karen S Flatten; Guy G Poirier; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-01-30       Impact factor: 12.531

2.  ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

Authors:  Neru Munshi; Sébastien Jeay; Youzhi Li; Chang-Rung Chen; Dennis S France; Mark A Ashwell; Jason Hill; Magdi M Moussa; David S Leggett; Chiang J Li
Journal:  Mol Cancer Ther       Date:  2010-05-18       Impact factor: 6.261

3.  Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Joachim von Pawel; Edward G Garmey; Wallace L Akerley; Wolfram Brugger; Dora Ferrari; Yinpu Chen; Daniel B Costa; David E Gerber; Sergey Orlov; Rodryg Ramlau; Susan Arthur; Igor Gorbachevsky; Brian Schwartz; Joan H Schiller
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

4.  Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.

Authors:  Xuesong Liu; Yan Shi; David X Maag; Joann P Palma; Melanie J Patterson; Paul A Ellis; Bruce W Surber; Damien B Ready; Niru B Soni; Uri S Ladror; Allison J Xu; Ramesh Iyer; John E Harlan; Larry R Solomon; Cherrie K Donawho; Thomas D Penning; Eric F Johnson; Alexander R Shoemaker
Journal:  Clin Cancer Res       Date:  2011-11-29       Impact factor: 12.531

5.  Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197.

Authors:  Sudharshan Eathiraj; Rocio Palma; Erika Volckova; Marscha Hirschi; Dennis S France; Mark A Ashwell; Thomas C K Chan
Journal:  J Biol Chem       Date:  2011-03-24       Impact factor: 5.157

6.  Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.

Authors:  Timothy A Yap; David Olmos; Andre T Brunetto; Nina Tunariu; Jorge Barriuso; Ruth Riisnaes; Lorna Pope; Jeremy Clark; Andrew Futreal; Michael Germuska; David Collins; Nandita M deSouza; Martin O Leach; Ronald E Savage; Carol Waghorne; Feng Chai; Edward Garmey; Brian Schwartz; Stan B Kaye; Johann S de Bono
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

7.  Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.

Authors:  Cristina Basilico; Selma Pennacchietti; Elisa Vigna; Cristina Chiriaco; Sabrina Arena; Alberto Bardelli; Donatella Valdembri; Guido Serini; Paolo Michieli
Journal:  Clin Cancer Res       Date:  2013-03-26       Impact factor: 12.531

8.  Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

Authors:  Ryohei Katayama; Aki Aoyama; Takao Yamori; Jie Qi; Tomoko Oh-hara; Youngchul Song; Jeffrey A Engelman; Naoya Fujita
Journal:  Cancer Res       Date:  2013-04-18       Impact factor: 12.701

9.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316
  9 in total
  15 in total

1.  KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.

Authors:  Dominic Leiser; Michaela Medová; Kei Mikami; Lluís Nisa; Deborah Stroka; Andree Blaukat; Friedhelm Bladt; Daniel M Aebersold; Yitzhak Zimmer
Journal:  Mol Oncol       Date:  2015-04-14       Impact factor: 6.603

2.  Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Authors:  Simona Cignetto; Chiara Modica; Cristina Chiriaco; Lara Fontani; Paola Milla; Paolo Michieli; Paolo M Comoglio; Elisa Vigna
Journal:  Mol Oncol       Date:  2016-03-28       Impact factor: 6.603

3.  MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.

Authors:  Hui Li; Chia-Wei Li; Xiaoqiang Li; Qingqing Ding; Lei Guo; Shuang Liu; Chunxiao Liu; Chien-Chen Lai; Jung-Mao Hsu; Qiongzhu Dong; Weiya Xia; Jennifer L Hsu; Hirohito Yamaguchi; Yi Du; Yun-Ju Lai; Xian Sun; Paul B Koller; Qinghai Ye; Mien-Chie Hung
Journal:  Gastroenterology       Date:  2019-01-31       Impact factor: 22.682

Review 4.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

5.  Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.

Authors:  Mark N Stein; Kim M Hirshfield; Hua Zhong; Eric A Singer; Siraj M Ali; Shridar Ganesan
Journal:  Eur Urol       Date:  2014-10-27       Impact factor: 20.096

6.  Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Authors:  Daniel Morgensztern; Meghan J Campo; Suzanne E Dahlberg; Robert C Doebele; Edward Garon; David E Gerber; Sarah B Goldberg; Peter S Hammerman; Rebecca S Heist; Thomas Hensing; Leora Horn; Suresh S Ramalingam; Charles M Rudin; Ravi Salgia; Lecia V Sequist; Alice T Shaw; George R Simon; Neeta Somaiah; David R Spigel; John Wrangle; David Johnson; Roy S Herbst; Paul Bunn; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

7.  GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells.

Authors:  Lily L Remsing Rix; Brent M Kuenzi; Yunting Luo; Elizabeth Remily-Wood; Fumi Kinose; Gabriela Wright; Jiannong Li; John M Koomen; Eric B Haura; Harshani R Lawrence; Uwe Rix
Journal:  ACS Chem Biol       Date:  2013-11-20       Impact factor: 5.100

8.  Molecular classification of hepatocellular carcinoma: potential therapeutic implications.

Authors:  Nicolas Goossens; Xiaochen Sun; Yujin Hoshida
Journal:  Hepat Oncol       Date:  2015

9.  Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer.

Authors:  Pierre Saintigny; William N William; Jean-Philippe Foy; Vassiliki Papadimitrakopoulou; Wenhua Lang; Li Zhang; You Hong Fan; Lei Feng; Edward S Kim; Adel K El-Naggar; J Jack Lee; Li Mao; Waun Ki Hong; Mark W Lingen; Scott M Lippman
Journal:  J Natl Cancer Inst       Date:  2018-03-01       Impact factor: 11.816

10.  Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.

Authors:  Tetsuo Mashima; Masaru Ushijima; Masaaki Matsuura; Satomi Tsukahara; Kazuhiro Kunimasa; Aki Furuno; Sakae Saito; Masami Kitamura; Taeko Soma-Nagae; Hiroyuki Seimiya; Shingo Dan; Takao Yamori; Akihiro Tomida
Journal:  Cancer Sci       Date:  2015-05-25       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.